BioMarin’s Vimizim (elosulfase alfa) Receives NMPA’s (CFDA) Approval for Treatment of Morquio A Syndrome

 BioMarin’s Vimizim (elosulfase alfa) Receives NMPA’s (CFDA) Approval for Treatment of Morquio A Syndrome

BioMarin’s Vimizim (elosulfase alfa) Receives NMPA’s (CFDA) Approval for Treatment of Morquio A Syndrome

Shots:

  • Biomarin has received approval for its Vimizim, as a first approval by NMPA for patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome
  • In May 2018, Chinese Drug Evaluation Center issued a list of rare diseases including MPS and in Aug 2018 is also released a list of 48 drugs which are eligible for Priority Review and already approved in the US, EU and Japan including Vimizim in China
  • Vimizim is an enzyme replacement therapy (ERT) developed to target Morquio A Syndrome and is used to treat 1300+ patients in 50+ countries

Click here to read full press release/ article | Ref: BioMarin | Image: Main menu

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post